Abiopharma

🔍 BLANKENSHIP C RONALD (Executive)

Company: REGENCY CENTERS CORP (REG)

Report Date: 2026-05-11

Detailed Transactions and Holdings:

• Acquired 1,875 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: M | equity_swap_involved: false | shares_owned_after: 114,679.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 77 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: M | equity_swap_involved: false | shares_owned_after: 114,756.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 1,875 shares of Restricted Stock (Derivative)
  Date: 2026-05-11 | Code: M | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 77 shares of Dividend Equivalent Rights (Derivative)
  Date: 2026-05-11 | Code: M | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F2, F2

Footnotes:

• F1: Vesting of restricted stock grant pursuant to Regency's Omnibus Incentive Plan.
• F2: Settlement of dividend equivalent rights in connection with vesting of restrictive stock. The rights accrued when and as dividends were paid on Regency's common stock and vested proportionately with the restricted stock. Each dividend equivalent is the equivalent of one share of Regency's common stock.